HOME >> MEDICINE >> NEWS
BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR Conference

tives. These results also demonstrate the ability of BioNumerik's Karenitecins to bypass common drug resistance mechanisms (MDR, MRP & LRP) to which many other camptothecins appear to be susceptible. Because its compounds are lipophilic, BioNumerik believes its Karenitecins will have enhanced tissue penetration, drug delivery and bioavailability compared to water soluble camptothecins.

Camptothecins, described as Topoisomerase I inhibitors, represent some of the most active anticancer drugs in existence. Due to formulation problems, however, the great majority of camptothecins in development or on the market have been made water soluble to allow easier drug dissolution and administration. BioNumerik believes that this approach may limit the utility of these drugs and the Company has developed a new generation of proprietary highly lipophilic (fat loving) camptothecins, known as Karentitecins, that have been designed to overcome problems that exist with camptothecin and the current camptothecin derivatives.

Using its mechanism-based approach, BioNumerik used its Cray supercomputers to construct a detailed computational model involving human Topoisomerase I and DNA in order to understand and more precisely target the key interactions between camptothecin-Topo I/DNA. BioNumerik used this information to guide and complement the discovery and optimization of novel compounds for laboratory synthesis and preclinical testing.

In a presentation titled "BNP7787: Administration In Vivo Results in Increased Therapeutic Index and Toxicity Reduction of Platinum Drugs", BioNumerik also presented data on its proprietary agent BNP7787, a novel water soluble disulfide that was engineered to increase the therapeutic index of cisplatin and carboplatin, two widely used anticancer drugs.

Although platinum chemotherapy is widespread, formulations of cisplatin and carboplatin have a major risk of kidney toxicity (cisplatin), nausea and vomiting, bone marrow suppressio
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
212-696-4455 x. 205
Noonan/Russo Communications
30-Mar-1998


Page: 1 2 3 4 5

Related medicine news :

1. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
2. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
5. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
6. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
10. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
11. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... Los Angeles, CA (PRWEB) , ... August 17, 2017 , ... ... Hardiman partners Mark Hardiman, John Mills and Harry Nelson. This is the third consecutive ... row for Nelson. Hardiman and Nelson were both recognized for expertise in Health Care ...
(Date:8/17/2017)... Washington, NY (PRWEB) , ... August 17, 2017 , ... ... systems alike, 2017 has brought a number of changes to the smartwatch market. As ... up almost 1.5 percentage points from the six months prior. Additionally, according to latest ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Momkus McCluskey ... newest Partner. Ms. Parks is a member of the firm’s Commercial Litigation and Employment ... and provides a wealth of knowledge in matters of employment litigation, commercial litigation and ...
(Date:8/17/2017)... ... August 17, 2017 , ... Navigating Cancer, ... Florida-based oncology business advisor to oncology practices, announced today the results of a ... attributable savings from resolving critical clinical issues that would have otherwise resulted in ...
(Date:8/16/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 ... ... list of the fastest growing companies in the U.S. for the second year in ... shown strong growth over the past three years. , “To be on the list ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/10/2017)... 10, 2017  Physical Rehabilitation Network (PRN), acquired the long-standing ... Lakewood, Colorado . The reputable clinic will continue to ... DPT with his staff of four clinicians. Lipkin received his ... brings over 10 years of experience with a strong background ... PT marks the 10th PRN clinic in and around the ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
Breaking Medicine Technology:
Cached News: